New combo therapy tested for deadly childhood brain cancer

NCT ID NCT01165333

Completed Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested whether adding the drug cilengitide to standard radiation is safe for children and young adults with a rare, aggressive brain tumor called DIPG. The main goal was to find the highest safe dose. 32 participants were enrolled. The study did not aim to cure the disease, but to gather safety information for future trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE INTRINSIC PONTINE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse intrinsic pontine glioma glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE INTRINSIC PONTINE GLIOMA

Contacts and locations

Locations

CHU

Toulouse, 33059, France
CHU, Hôpital d'Enfants de la Timone

Marseille, 13385, France
Centre Hospitalier Universitaire de Nantes

Nantes, 44093, France
Centre Léon Bérard

Lyon, 69373, France
Centre Oscar Lambret

Lille, 59020, France
Hôpital des Enfants, Groupe Hospitalier

Bordeaux, 33076, France
Hôpitaux Universitaires de Strasbourg

Strasbourg, 67091, France
Institut Curie

Paris, 75231, France
Institut Gustave-Roussy

Villejuif, 94805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.